Axsome Therap (AXSM.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec5

Axsome Therapeutics Inc. CEO Disposes of Company Common Stock

00:40

Dec3

Mizuho Maintains Buy Rating on Axsome Therapeutics, Price Target at $202

14:17

Nov24

DNB Asset Management Increases Stake in Axsome Therapeutics

09:49

Nov12

Axsome Therapeutics Acquires Avenue Therapeutics Subsidiary and BAER-101 Rights

13:03

Nov10

Mizuho Securities analyst reiterates Axsome Therapeutics buy rating

12:42

Nov7

Mizuho Raises Axsome Therapeutics Price Target to $202

17:01

Schedules & Filings

Schedules

Filings

Nov3

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 170.99 M, Net Income -47.23 M, EPS -0.9441

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 150.04 M, Net Income -47.97 M, EPS -0.9702

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 121.46 M, Net Income -59.41 M, EPS -1.22

Axsome Therapeutics, Inc. (AXSM.US) Q1 2025 Earnings Conference Call

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change